NYSE:ABT - Abbott Laboratories Stock Price, News, & Analysis

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Abbott Laboratories announced a quarterly dividend on Friday, December 14th. Shareholders of record on Tuesday, January 15th will be given a dividend of $0.32 per share on Friday, February 15th. This represents a $1.28 annualized dividend and a yield of 1.82%. This is a boost from Abbott Laboratories's previous quarterly dividend of $0.28. View Abbott Laboratories' Dividend History.

Abbott Laboratories (NYSE:ABT) posted its earnings results on Wednesday, October, 17th. The healthcare product maker reported $0.75 earnings per share for the quarter, meeting analysts' consensus estimates of $0.75. The healthcare product maker earned $7.66 billion during the quarter, compared to the consensus estimate of $7.65 billion. Abbott Laboratories had a net margin of 2.91% and a return on equity of 16.05%. The company's quarterly revenue was up 12.1% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.66 EPS. View Abbott Laboratories' Earnings History.

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, January 23rd 2019. View Earnings Estimates for Abbott Laboratories.

Abbott Laboratories updated its FY18 earnings guidance on Wednesday, October, 17th. The company provided earnings per share guidance of $2.87-2.89 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.88. Abbott Laboratories also updated its FY 2018 guidance to $2.87-2.89 EPS.

20 analysts have issued 1-year price targets for Abbott Laboratories' stock. Their forecasts range from $64.00 to $86.00. On average, they expect Abbott Laboratories' stock price to reach $75.5842 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price. View Analyst Price Targets for Abbott Laboratories.

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 4 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Abbott Laboratories.

News coverage about ABT stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Abbott Laboratories earned a media sentiment score of 1.0 on InfoTrie's scale. They also assigned news coverage about the healthcare product maker a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Some companies that are related to Abbott Laboratories include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), AbbVie (ABBV), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Shire (SHPG) and Allergan (AGN).

Abbott Laboratories' stock is owned by a number of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (7.91%), Vanguard Group Inc (7.91%), Capital Research Global Investors (7.13%), BlackRock Inc. (6.67%), Massachusetts Financial Services Co. MA (2.20%) and Bank of New York Mellon Corp (1.55%). Company insiders that own Abbott Laboratories stock include Alejandro D Wellisch, Andrew H Lane, Brian J Blaser, Daniel Gesua Sive Salvadori, Daniel J Starks, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Pederson, Michael J Warmuth, Miles D White, Robert E Funck, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

ABT stock was sold by a variety of institutional investors in the last quarter, including Capital Research Global Investors, Mitsubishi UFJ Trust & Banking Corp, TIAA CREF Investment Management LLC, Marshall Wace North America L.P., Diamond Hill Capital Management Inc., Alliancebernstein L.P., Canada Pension Plan Investment Board and Bahl & Gaynor Inc.. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrew H Lane, Brian J Blaser, Daniel Gesua Sive Salvadori, Jaime Contreras, Jared Watkin, Michael J Pederson, Miles D White, Roger Bird, Sharon J Bracken and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

ABT stock was acquired by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Capital International Investors, Matthew Goff Investment Advisor LLC, Vanguard Group Inc, Vanguard Group Inc., Capital World Investors, Federated Investors Inc. PA and Sustainable Growth Advisers LP. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser and Daniel J Starks. View Insider Buying and Selling for Abbott Laboratories.

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ABT stock can currently be purchased for approximately $70.1385.

Abbott Laboratories has a market capitalization of $124.28 billion and generates $27.39 billion in revenue each year. The healthcare product maker earns $477 million in net income (profit) each year or $2.50 on an earnings per share basis. Abbott Laboratories employs 99,000 workers across the globe.

The official website for Abbott Laboratories is http://www.abbott.com.

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.